XTL Biopharmaceuticals Ltd. announced a private placement of 1,500,000 units at a price of $1 per unit for the gross proceeds of $1,500,000 in funding on March 20, 2024. Each unit consisting of one ADS and one warrant, such warrant may be exercised during a period of five years from its issuance into one ADS at an exercise price of $1.20 per warrant. Consummation of the Private Placement is conditioned upon customary closing conditions and obtaining shareholders?

approval as Alexander Rabinovich, a 23.5% shareholder and a director of the company, is one of the investors in this Private Placement. The company announced that it will hold an Extraordinary General Meeting of Shareholders on April 30, 2024.